0000000000161706

AUTHOR

Daniela Verdanova

showing 1 related works from this author

Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalen…

2020

Abstract Background We assessed the 10-year efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV) or one dose of a monovalent varicella vaccine (V) in children from Czech Republic, Lithuania, Poland, Romania and Slovakia. Methods This was a phase IIIB follow-up of an observer-blind, randomized, controlled trial (NCT00226499). In phase A, healthy children aged 12–22 months from 10 European countries were randomized in a 3:3:1 ratio to receive two doses of MMRV (MMRV group), one dose of MMR followed by one dose of V (MMR + V group), or two doses of MMR (MMR; control group), 42 days apart. Vaccine efficacy (VE) against varicella (confirme…

Slovakiamedicine.medical_specialtyVaricella vaccineAntibodies Viralmedicine.disease_causelaw.inventionChickenpox Vaccine03 medical and health sciences0302 clinical medicineRandomized controlled triallaw030225 pediatricsInternal medicineEpidemiologymedicineHumansVaccines Combined030212 general & internal medicineChildAdverse effectMumpsRubellaCzech RepublicGeneral VeterinaryGeneral Immunology and MicrobiologyRomaniabusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthVaricella zoster virusInfantVaccine efficacyConfidence intervalEuropeInfectious DiseasesMolecular MedicinePolandbusinesschildren ; efficacy ; live-attenuated varicella vaccine ; long-term follow-up ; measles-mumps-rubella ; varicella zoster virusMeasles-Mumps-Rubella VaccineFollow-Up StudiesMeaslesVaccine
researchProduct